At the 1-year clinical follow-up ( 100 % of patients ) , the main clinical outcome measure ( composite of cardiac death , myocardial infarction , and target vessel revascularization ) was significantly reduced in the EES arm ( 10 % vs. 18 % ; p = 0.04 ; hazard ratio : 0.58 ; 95 % CI : 0.35 to 0.98 ) , mainly driven by a lower need for target vessel revascularization ( 8 % vs. 16 % ; p = 0.035 ) .